Variant Summary
- Also known as
- EML4-NTRK3
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 15
Evidence Level Distribution
Level C: 13Level D: 2
Evidence Items
Showing CIViC evidence rows where gene = EML4::NTRK3 and variant = Fusion.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Oncogenic | Supports | Oncogenicity | Congenital Fibrosarcoma | 4 | |
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Entrectinib | 4 |
| C | Diagnostic | Supports | Positive | Congenital Fibrosarcoma | 3 | |
| C | Diagnostic | Supports | Positive | Congenital Mesoblastic Nephroma | 3 | |
| D | Oncogenic | Supports | Oncogenicity | Colon Cancer | 3 | |
| C | Predictive | Supports | Sensitivity/Response | High Grade Glioma | Larotrectinib | 3 |
| C | Diagnostic | Supports | Positive | Congenital Fibrosarcoma | 3 | |
| C | Predictive | Supports | Sensitivity/Response | Papillary Thyroid Carcinoma | Entrectinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Entrectinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Congenital Fibrosarcoma | Entrectinib | 2 |
| C | Oncogenic | Supports | Oncogenicity | Cervical Sarcoma | 1 | |
| C | Oncogenic | Supports | Oncogenicity | Pancreatic Ductal Adenocarcinoma | 1 | |
| C | Oncogenic | Supports | Oncogenicity | Colon Adenocarcinoma | 1 | |
| C | Oncogenic | Supports | Oncogenicity | Glioblastoma | 1 | |
| C | Oncogenic | Supports | Oncogenicity | Poorly Differentiated Thyroid Carcinoma | 1 |